Table 1.
Baseline demographic and surgery characteristics
| Characteristics | Placebo (n = 81) | ASP1128 (n = 69) | Observational cohort (n = 200) |
|---|---|---|---|
| Demography/medical history | |||
| Age (yr) | 68.7 (9.4) | 68.0 (8.3) | 69.4 (8.8) |
| Sex (females) | 7 (8.6) | 16 (23.2) | 65 (32.5) |
| Weight (kg) | 95.9 (19.8) | 94.9 (22.4) | 92.1 (19.2) |
| LVEF (%) | 51.6 (11.5) | 53.8 (9.1) | 55.1 (10.3) |
| PAD at screening | 10 (12.3) | 15 (21.7) | 20 (10.0) |
| CKD at screening | 21 (25.9) | 6 (8.7) | 37 (18.5) |
| Surgery parameters | |||
| CABG (no valve surgery) | 49 (60.5) | 34 (49.3) | 122 (61.0) |
| CABG + valve surgery | 18 (22.2) | 12 (17.4) | 33 (16.5) |
| Valve surgery (no CABG) | 14 (17.3) | 23 (33.3) | 45 (22.5) |
| Mitral valve | 12 (14.8) | 21 (30.4) | 28 (14.0) |
| Aortic valve | 26 (32.1) | 17 (24.6) | 56 (28.0) |
| Tricuspid valve | 5 (6.2) | 11 (15.9) | 4 (2.0) |
| CPB (h) | 2.15 (0.93) | 2.24 (1.26) | 1.87 (0.72) |
| Aortic cross-clamping (h) | 1.52 (0.64) | 1.62 (0.87) | 1.40 (0.54) |
| Volume of blood loss during surgery (ml) | 481.7 (562.0) | 412.7 (455.2) | 351.9 (381.7) |
| Baseline kidney function laboratory values | |||
| T2.I7 ([ng/ml]2/1000) | 0.70 (0.66) | 0.69 (0.50) | 0.13 (0.07) |
| Serum creatinine (mg/dl) | 0.99 (0.25) | 0.90 (0.23) | 0.96 (0.26) |
| eGFR based on SCra (ml/min per 1.73 m2) | 76.9 (18.8) | 82.5 (16.7) | 75.9 (18.8) |
| eGFR based on cystatin-Cb (ml/min per 1.73 m2) | 66.2 (22.1) | 72.6 (22.6) | 62.2 (19.5) |
CABG, coronary artery bypass grafting; CKD, chronic kidney disease; CPB, cardio-pulmonary bypass pump; LVEF, left ventricular ejection fraction; PAD, peripheral arterial disease; SCr, serum creatinine; SD, standard deviation.
Mean (SD) for continuous parameters, N (%) for categorical parameters.
a
Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] equation13.
b
2012 CKD-EPI cystatin-C equation13.